Key result
Dobutamine-cardiac magnetic resonance with late gadolinium enhancement provides the best accuracy for evaluating myocardial viability and predicting revascularization benefit in ischemic cardiomyopathy.
This review highlights dobutamine-cardiac magnetic resonance with late gadolinium enhancement as the most accurate tool for assessing myocardial viability and guiding revascularization in patients with ischemic left ventricular systolic dysfunction.
Answers are grounded in this paper and cite their sources.
Supports dobutamine-CMR with LGE for viability assessment in ischemic cardiomyopathy; leaves open need for prospective trials before changing practice.
Coronary artery disease (CAD) associated with left ventricular systolic dysfunction is a condition related to poor prognosis. There is a lack of robust evidence in many aspects related to this condition, from definition to treatment. Ischemic cardiomyopathy is a spectrum ranging from stunned myocardium associated with myocardial fibrosis to hibernating myocardium and repetitive episodes of ischemia. In clinical practice, relevance lies in identifying the myocardium that has the ability to recover its contractile reserve after revascularization. Methods to evaluate cellular integrity tend to have higher sensitivity, while the ones assessing contractile reserve have greater specificity, since a larger mass of viable myocytes is required in order to generate contractility change. Since there are many methods and different ways to detect viability, sensitivity and specificity vary widely. Dobutamine-cardiac magnetic resonance with late gadolinium enhancement has the best accuracy is this setting, giving important predictors of prognostic and revascularization benefit such as scar burden, contractile reserve and end-systolic volume index. The latter has shown differential benefit with revascularization in some recent trials. Finally, authors discuss interventional procedures in this population, focusing on coronary artery bypass grafting and evolution of evidence from CASS to post-STICH era.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2017) conducted a review in Ischemic left ventricle systolic dysfunction. Diagnostic tools and therapeutics was evaluated. Dobutamine-cardiac magnetic resonance with late gadolinium enhancement provides the best accuracy for evaluating myocardial viability and predicting revascularization benefit in ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: